secwatch.observer — SEC 8-K summary
======================================

Issuer:     AGIOS PHARMACEUTICALS, INC. (AGIO)
CIK:        0001439222
Form:       8-K
Filed at:   2023-03-03T23:59:59+00:00
Accession:  0001193125-23-060031
Event type: other
Sentiment:  neutral
Materiality: 0.10
Item codes: 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Agios Pharmaceuticals amends bylaws to update proxy rules and meeting procedures
--------------------------------------------------------------------------------

- Revised procedural mechanics for stockholder nominations under universal proxy rules.
- Requires additional background info and representations from proposing stockholders.
- Clarifies that failure to comply with Rule 14a-19 may result in disregarding nominations.
- Eliminates requirement to make stockholder list available during meeting.
- Adds emergency provisions limiting officer/director liability to willful misconduct.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1439222/000119312523060031/0001193125-23-060031-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1439222/000119312523060031/d638020d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-060031

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer